P
neumocystis jiroveci pneumonia (PJP) continues to be a serious problem among immunocompromised patients despite the decreased number of cases among human immunodeficiency virus (HIV)-infected patients over the past decade with the widespread use of prophylaxis. The high mortality of patients requiring mechanical ventilation has remained unchanged, ranging from 50 to 60% (35) . Although the gold standard for diagnosis is microscopic visualization of the organism, the methods are not sensitive, particularly in HIV-negative patients (31) .
The incidence of invasive fungal infection (IFI) has been increasing, especially among immunocompromised patients undergoing aggressive chemotherapy for cancer, bone marrow and organ transplantation, and advanced critical care. Despite advances in therapy, IFI is associated with considerable morbidity and a mortality rate of 30 to 70% for aspergillosis and 40 to 50% for candidiasis (15) . Diagnosis of IFI is challenging because clinical and radiological signs and conventional microbiological and histological techniques are not sensitive enough (25) . For these reasons, intensive research currently aims at the development of new diagnostic methods for PJP and IFI.
One of these new diagnostic techniques is the assay for the serum 1,3-␤-D-glucan (BG) derived from major cell wall components of various medically important fungi. The Fungitell test (Associates of Cape Cod, Inc., East Falmouth, MA) is a chromogenic kinetic test that was approved in 2003 by the U.S. Food and Drug Administration for the presumptive diagnosis of IFI. The BG assay has been used frequently, and the results are included in the revised IFI diagnosis criteria of the European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/ MSG) criteria (11) . However, the results of test performances have varied, as Nakamura and colleagues (42) suggested that the detection rate of BG in HIV-negative patients was lower than that in HIV patients.
One systematic review (23) on the accuracy of BG assay only for diagnosing IFI has recently been published. The review did not assess the diagnostic accuracy for PJP. The article included 2 of 16 evaluated studies using inappropriate reference standards; such inappropriate reference standards, according to the EORTC/ MSG, consisted of only mycological criteria (22, 39) . The review also used language restrictions and did not investigate possible explanations for the observed heterogeneity. We report a new systematic review of the accuracy of the BG assay for diagnosing PJP and IFI. We also focus on study design, reference standard, and assay as explanations for between-study variability in diagnostic accuracy.
MATERIALS AND METHODS
Data sources and searches. We developed a protocol for the review by following standard reporting guidelines (7, 21) . The search was carried out using four different databases (MEDLINE, Web of Science, Cochrane Collaboration databases, and Ichushi-Web) from January 1966 until No-vember 2010. Ichushi-Web, which is a major Japanese database, was included because the BG assay was first developed in Japan. The term "diagnosis" and the medical subject heading terms "fungi," "mycoses," and "beta-glucans" were used for searching MEDLINE, the terms "glucan" and "diagnosis" for searching the Web of Science and Cochrane Collaboration databases, and the terms "fungi," "mycoses," "Pneumocystis," "carinii," "jiroveci," "aspergillosis," "Aspergillus," "Candida," "candidiasis," "glucan," and "diagnosis" for searching Ichushi-Web. Reference lists of retrieved studies and review articles were also reviewed. Only papers published in full text were selected, while no language restrictions were applied to the search.
Study selection. Studies relevant for determining the diagnostic validity of serum BG assay for PJP and IFI in humans were included if two sets of criteria were met. First, positive findings for cytological or direct microscopic examination of sputum or bronchoalveolar lavage fluid for PJP and the proven or probable presence of IFI according to the EORTC/MSG criteria (5) or similar criteria for IFI as a reference standard. If a study used both positive findings for cytological or microscopic examination and positive PCR as a reference standard for PJP, we excluded participants who had been diagnosed with positive PCR. Second, absolute numbers of true-positive, false-negative, true-negative, and false-positive observations were available or could be derived from the reported data. Only major fungi such as invasive candidiasis and invasive aspergillosis were included in the IFI group because the number of the other fungi was small in included studies and certain zygomycetes (Mucor and Rhizopus species) and because Cryptococcus species had no BG cell wall. Case reports and review articles were excluded. If a study appeared to meet selection criteria but had a patient population that appeared to be the same as or to overlap with the patient population of a similar study, we included the larger of the studies.
Data extraction and study quality assessment. We wanted to extract the following variables: publication year; name(s) and institution(s) of the author(s); information on the original sample source; study design; patient demographics and comorbidities; type of invasive fungal infection; characteristics of control subjects; numbers of true-positive, falsenegative, true-negative, and false-positive observations; type and manufacturer of the BG assay; reference standard; cutoff values for definition of a positive BG test result; and blinding of investigators to results.
Two investigators independently rated the quality of the findings by using a modified version of the Quality Assessment for Diagnostic Accuracy Studies (QUADAS) tool (58) , which contains 11 items specifically developed to assess the quality of systematic reviews of primary studies of diagnostic tests, and is recommended by the Cochrane Diagnostic Reviewers' Handbook (52) . As recommended by the designers of the QUADAS tool, we did not apply weights to the QUADAS item or use a summary score in the analysis. Instead, we used subgroup analyses to explore whether scores on the following quality items explained variation in diagnostic performance: representative spectrum, acceptable reference standard, differential verification avoided, and index test results blinded. These items have been shown to result in biased estimates of the diagnostic performance (30, 53) . We resolved discrepancies about any item through discussion.
Data synthesis and analysis. For main outcomes, we evaluated the diagnostic accuracy of the serum BG assay for PJP and for IFI. Subgroup analyses were performed only when each subgroup included data of at least three diagnostic studies. If several cutoffs were reported in one study, we used the cutoff that offered the best test performance. A randomeffects model was used to combine estimates of sensitivity, specificity, diagnostic odds ratio (DOR), and area under the summary receiver operating characteristic curve (AUC-SROC) with 95% confidence interval (95% CI) (10, 37) . We also assessed heterogeneity by means of the Cochran Q method and the test of inconsistency (I 2 )(9, 18). Sensitivity analysis was based on control participants, exclusion of possible IFI in control patients, language, and prophylactic antifungal therapy. We conducted a stratified analysis for study design, the brand-name assay, the reference standard, the kind of mycosis, and the QUADAS item and used metaregression to identify the possible sources of heterogeneity among studies (41) . We explored the possibility of publication bias by means of funnel plots and the Egger test for diagnostic odds ratios (13, 55) . For all analyses, we used MetaDiSc, version 1.4 (Hospital Universitario Ramón y Cajal, Madrid, Spain) and Comprehensive Meta Analysis version 2 (Biostat Inc., Englewood, CA).
RESULTS
Search results and characteristics of studies. We identified 907 possibly relevant articles from four different databases (MEDLINE, Web of Science, Cochrane Collaboration databases, and Ichushi-Web), and 96 full-length articles were selected for detailed analysis on the basis of title or abstract. Retrieval and inclusion flow is shown in Fig. 1 . Eventually, 35 articles met the inclusion criteria (1-4, 12, 14, 16, 17, 19, 20, 24, 26, 27, 29, 32-34, 38, 40, 43-51, 54, 56, 57, 59-62) , but since the article by Odabasi et al. (45) included two studies, a case-control study and a retrospective cohort study, 36 studies in all were included. Twelve studies were included for PJP and 31 studies for IFI. The characteristics of these studies are outlined in Tables 1, 2 , and 3. A total of 5,453 participants were covered by the studies, with women accounting for a median of 43.3%, and the median of the mean or median age was 55.1 years (interquartile range, 47.0 to 58.3 years). Hematological disorders constituted the underlying diseases of most patients. Characteristics of control groups varied, with most studies using patients with hematological disorders. The two studies published by Obayashi and colleagues included different patient cohorts, one study analyzing 50 patients who were enrolled in 1992 and 1993 at nine hospitals in Japan (43) and the other study 58 patients who had been enrolled from 2000 to 2005 and who had undergone autopsy after death (44) .
The 36 studies included six assays: 17 used Fungitell (1, 3, 4, 12, 16, 17, 27, 29, 34, (45) (46) (47) (48) (49) (50) (51) , 9 used the Fungitec G test (2, 20, 26, 33, 43, 44, 57, 59, 60) , 6 used the Wako ␤-glucan test (14, 19, 24, 40, 54, 56) , 3 used the GKT-25 M set (32, 61, 62) , and 1 used the fungal index (38) . All studies but one were based in 1 of 13 countries, with the majority of assays in Japan (n ϭ 13), as well as in the United States (n ϭ 7), China (n ϭ 4), Spain (n ϭ 2), Austria (n ϭ 1), Belgium (n ϭ 1), Czech Republic (n ϭ 1), France (n ϭ 1), Germany (n ϭ 1), Kuwait (n ϭ 1), The Netherlands (n ϭ 1), Sweden (n ϭ 1), and Switzerland (n ϭ 1); one study that performed assays in multiple countries (Spain, Argentina, and France) was also included. Prophylactic antifungal therapy was used in 12 studies. Assessment of study quality. Table 4 presents the results of the quality assessment. All studies used acceptable reference standard and avoided differential verification bias. Incorporation bias was avoided in 97% (35 of 36) of the studies. Most studies did not report whether the interpreters of BG results were blinded to the final diagnosis and vice versa. We therefore conducted stratification based only on the representative spectrum item among preplanned subgroup analyses. A cohort design rather than a casecontrol design was used by 47% (17 of Table 5 shows the pooled analysis findings for sensitivity, specificity, DOR, and AUC-SROC of the BG assay for PJP and IFI. The pooled findings for PJP showed sensitivity of 96% (95% CI, 92% to 98%), specificity of 84% (95% CI, 83% to 86%), DOR of 102.3 (95% CI, 59.2 to 176.6), and AUC-SROC of 0.96 (95% CI, 0.94 to 0.99). The DOR was not heterogeneous (Q ϭ 7.24; P ϭ 0.77; I 2 ϭ 0%). The SROC curve is shown in Fig. 2 .
Of the 12 included studies for PJP, 5 studies for patients with HIV (1, 12, 48, 57, 59) and 5 studies for HIV-negative patients (2, 12, 27, 40, 48) provided specific data for the diagnostic accuracy of the BG assay. The diagnostic accuracy was not significantly different between HIV patients and HIV-negative patients (Table 5) .
Stratification based on findings of the brand-name assay, study design, or QUADAS item (representative spectrum) did not produce statistically significant differences in the accuracy of the BG assay, either. When we excluded studies including healthy controls or blood donors, no statistically significant differences in the accuracy of the BG assay were noted. Even after the exclusion of studies written in languages other than English, the results did not change significantly. In the result of multivariable metaregression, DOR was not significantly influenced by language, the brandname assay, study design, age, or sex.
Diagnostic accuracy for IFI. The pooled findings for IFI showed sensitivity of 80% (95% CI, 77% to 82%), specificity of 82% (95% CI, 81% to 83%), DOR of 25.7 (95% CI, 15.0 to 44.1), and AUC-SROC of 0.88 (95% CI, 0.82 to 0.93) ( Table 5 ). The DOR was significantly heterogeneous (Q ϭ 144.33; P Ͻ 0.001; I 2 ϭ 79%). The SROC curve is shown in Fig. 2 .
In 17 cohort studies (1, 2, 4, 16, 19, 20, 24, 29, 30, 34, 45, 47, 50, 51, 54, 61, 62) , the pooled sensitivity, specificity, DOR, and AUC-SROC were 72% (95% CI, 67% to 77%), 78% (95% CI, 76% to 80%), 12.3 (95% CI, 6.0 to 25.1), and 0.79 (95% CI, 0.73 to 0.85), respectively. In 14 case-control studies (3, 14, 26, 27, 33, 38, 40, 43-46, 48, 49, 60) , the pooled sensitivity, specificity, DOR, and AUC-SROC for IFI were 83% (95% CI, 80% to 86%), 86% (95% CI, 84% to 88%), 68.3 (95% CI, 30.7 to 151.8), and 0.95 (95% CI, 0.92 to 0.98), respectively. AUC-SROC was significantly lower in cohort studies than in case-control studies (P Ͻ 0.001) ( Table 5) . This difference was attributable to both significantly low sensitivity and significantly low specificity in the cohort study. When we conducted subgroup analysis for a reference standard, AUC-SROC of EORTC/MSG criteria and similar criteria were 0.80 (95% CI, 0.73 to 0.86) and 0.95 (95% CI, 0.90 to 0.99). The diagnostic accuracy was significantly lower in EORTC/MSG criteria than in similar criteria. Because the pooled specificity was similar, the lower diagnostic accuracy of EORTC/MSG criteria was mainly attributable to lower sensitivity. When stratified analysis was conducted based on findings of the brand-name assay, AUC-SROC of Fungitell, Fungitec G test, and Wako were 0.86 (95% CI, 0.79 to 0.93), 0.96 (95% CI, 9.96 to 1.00), and 0.94 (95% CI, 0.86 to 1.00).
Fungitell had an accuracy statistically lower than that of the Fungitec G test or Wako. Fungitell was lower in both sensitivity and specificity. Subgroup analysis within the QUADAS item (representative spectrum) showed lower accuracy in the no-bias group than in the potential-bias group.
Of the 31 included studies for IFI, 19 studies for invasive candidiasis (2-4, 14, 16, 19, 26, 27, 29, 34, 38, 40, 44-46, 48, 49, 61) and 17 studies for invasive aspergillosis (1, 2, 4, 16, 19, 20, 24, 27, 38, 40, 44-48, 51, 61) provided specific data for the diagnostic accuracy of the BG assay. When we conducted subgroup analysis for underlying disease, the pooled findings for invasive candidiasis showed sensitivity of 81% (95% CI, 77% to 85%), specificity of 81% (95% CI, 80% to 83%), DOR of 25.7 (95% CI, 12.9 to 51.2), and AUC-SROC of 0.90 (95% CI, 0.85 to 0.95). The pooled findings for invasive aspergillosis showed sensitivity of 77% (95% CI, 71% to 82%), specificity of 83% (95% CI, 82% to 85%), DOR of 23.2 (95% CI, 9.9 to 54.4), and AUC-SROC of 0.86 (95% CI, 0.77 to 0.94) ( Table 5 ). The diagnostic accuracies for invasive candidiasis and invasive aspergillosis were not significantly different.
When we excluded studies including healthy controls, studies in which diagnostic performance was analyzed per episode and not per patient, or studies including possible IFI in control popu- lation, no statistically significant differences in the accuracy of the BG assay were noted. Even after the exclusion of studies written in languages other than English and studies in which prophylactic antifungal therapy was not reported or used, the results did not change significantly. In the multivariable metaregression results, DOR was not significantly influenced by language, reference standard, age, or sex. Although we performed sensitivity analysis, stratified analysis, and metaregression based on various factors to determine the source of this majority of heterogeneity among the studies, heterogeneity was still significant. Publication bias. The appearance of funnel plots was asymmetrical, and Egger's test results were significant (P ϭ 0.01). This suggested that publication bias may be present. After exclusion of the four studies that included 50 or fewer participants, differences in the accuracy of the BG assay findings were not statistically significant.
DISCUSSION
Our meta-analysis to examine the diagnostic accuracy of the serum BG assay for PJP and IFI has resulted in several significant findings.
First, the BG assay showed the high AUC-SROC for PJP with no heterogeneity. Moreover, the BG assay is not an invasive test. The gold standard for diagnosis is microscopic visualization of the organism, and bronchoalveolar lavage fluid, sputum, or tissue is necessary for diagnosis. Because patients with PJP tend to present with nonproductive or minimally productive cough, sputum is often insufficient for diagnosis and an invasive procedure such as bronchoscopy is needed. Noninvasive BG assay is useful as a screen to avoid unnecessary invasive procedures.
Second, we showed that the BG assays have high sensitivity for PJP. The BG assay can therefore be used as a screening tool. If any of the BG assays are negative, PJP can be ruled out and unnecessary procedures or treatments for PJP can be avoided.
Third, the pooled specificity was moderate for PJP because the BG assay could be positive for various fungal infections and the presence of factors such as use of intravenous amoxicillinclavulanic acid, treatment of patients with immunological preparations (albumins or globulins), use of cellulose membranes and filters made from cellulose in hemodialysis, and use of cotton gauze swabs/packs/pads and sponges during surgery (8) . If the BG assay is positive, it is important to consider the factor associated with false-positive results and exclude IFI by other modalities or invasive procedures such as computed tomography scan and bronchoscopy.
Fourth, the diagnostic accuracies for HIV patients and HIVnegative patients were not significantly different. Nakamura and colleagues (42) suggested that the detection rate of BG in HIVnegative patients was lower than that in HIV patients. HIVnegative patients usually have significantly fewer organisms in bronchoalveolar lavage fluid than do HIV patients. This can lead to false-negative results, particularly in HIV-negative patients (8) . However, our results showed that the BG assay was useful not only in HIV patients but also in HIV-negative patients.
Fifth, the diagnostic accuracy for IFI of the BG assay was moderate, with high statistical heterogeneity. While there are several molecular and serological assays for the diagnosis of specific types of IFI, which can be detected by means of galactomannan, mannan, and DNA sequences (36) , only the BG assay can be used for various fungal infections. For instance, the diagnostic accuracy of the galactomannan assay for invasive aspergillosis is similar to that of BG for IFI. Leeflang and colleagues (28) used a meta-analysis to demonstrate that the galactomannan assay had an overall sensitivity of 78% (95% CI, 61% to 89%) and an overall specificity of 81% (95% CI, 72% to 88%) for proven or probable cases of invasive aspergillosis. However, patients at risk for one type of IFI are often at risk for one or more other types of IFI. Because both the sensitivity and the specificity of the BG assay are moderate for IFI, combination with other modalities and procedures is necessary to either rule out or rule in IFI. Therefore, it is reasonable that the BG assay positivity is used only as a mycological criterion in the revised EORTC/MSG criteria.
The summary results from our overall analysis for IFI are similar to those of the earlier review of Karageorgopoulos and colleagues (sensitivity, 80% vs. 77%; specificity, 82% vs. 85%; AUC-SROC, 0.88 vs. 0.89) (23) . However, Karageorgopoulos and colleagues included only 23 studies because of language restrictions and did not stratify their final analysis by study design or reference standard. Our meta-analysis showed that the substantial between-study heterogeneity for IFI resulted from differences in study design, reference standard, brand-name assay, and QUADAS item. We observed that case-control studies seemed to overestimate both sensitivity and specificity (3, 14, 26, 27, 33, 38, 40, 43-46, 48, 49, 60) . We also observed that the sensitivity of the EORTC/MSG criteria was lower than that of similar criteria (1, 2, 4, 16, 19, 20, 24, 27, 32, 45-48, 51, 54, 61, 62) . Fungitell was statistically lower in accuracy than Fungitec G test or Wako. Subgroup analysis within the QUADAS item (representative spectrum) showed lower accuracy in the no-bias group than in the potential-bias group. Well-designed, high-quality prospective cohort studies on the BG assay for IFI are needed.
Only one study, that by Alexander and colleagues (4), reported low diagnostic accuracy for IFI in lung transplants. These authors suggested that the BG assay might have limited utility as a screening tool for lung transplants. However, further studies are needed to confirm these findings of this study, because the sample size was small.
Our review has several limitations. First, there was evidence of publication bias, so it is possible that our results constitute an overestimation of the performance of the test. However, when we excluded small studies that have a greater tendency to overestimate diagnostic performance, differences in the accuracy of the BG assay still were not statistically significant. It is thus reasonable to conclude that the effect of publication bias was only minor (6) .
Second, the quality of our included studies was moderate. The bias in which low-quality studies overestimate test performance has been seen previously in studies of diagnostic tests (30, 53) . Although this relationship was found for diagnostic accuracy for IFI, stratification based on findings of the QUADAS item (representative spectrum) for PJP did not produce statistically significant differences in the accuracy of the BG assay.
In conclusion, the diagnostic accuracy of the BG assay is high for PJP and moderate for IFI. Because the sensitivity for PJP is particularly high, the BG assay can be used as a screening tool for PJP.
